These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 30779479)

  • 1. Pharmacokinetics, Food Effect, Ketoconazole Interaction, and Safety of JTK-853, a Novel Nonnucleoside HCV Polymerase Inhibitor, After Ascending Single and Multiple Doses in Healthy Subjects.
    Tamaki S; Shibata T; Hunt T; Gerhardt B; Yamada H; Pai SM
    Clin Pharmacol Drug Dev; 2019 Apr; 8(3):371-384. PubMed ID: 30779479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical characterization of JTK-853, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
    Ando I; Adachi T; Ogura N; Toyonaga Y; Sugimoto K; Abe H; Kamada M; Noguchi T
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4250-6. PubMed ID: 22615294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor.
    Mallalieu NL; Rahimy MH; Crowley CA; Appleman JR; Smith PF; Freddo JL
    Clin Ther; 2014 Dec; 36(12):2047-2063.e3. PubMed ID: 25456558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection.
    Sims KD; Lemm J; Eley T; Liu M; Berglind A; Sherman D; Lawitz E; Vutikullird AB; Tebas P; Gao M; Pasquinelli C; Grasela DM
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3496-503. PubMed ID: 24733462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.
    de Bruijne J; van Vliet A; Weegink CJ; Mazur W; Wiercinska-Drapało A; Simon K; Cholewińska-Szymańska G; Kapocsi J; Várkonyi I; Zhou XJ; Temam MF; Molles J; Chen J; Pietropaolo K; McCarville JF; Sullivan-Bólyai JZ; Mayers D; Reesink H
    Antivir Ther; 2012; 17(4):633-42. PubMed ID: 22427481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypic and phenotypic analyses of hepatitis C virus from patients treated with JTK-853 in a three-day monotherapy.
    Ogura N; Toyonaga Y; Ando I; Hirahara K; Shibata T; Turcanu G; Pai S; Yee K; Gerhardt B; Rodriguez-Torres M; Noguchi T
    Antimicrob Agents Chemother; 2013 Jan; 57(1):436-44. PubMed ID: 23129048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
    Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
    Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects.
    Muehler A; Kohlhof H; Groeppel M; Vitt D
    Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):557-573. PubMed ID: 32361977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
    Reesink HW; Fanning GC; Farha KA; Weegink C; Van Vliet A; Van 't Klooster G; Lenz O; Aharchi F; Mariën K; Van Remoortere P; de Kock H; Broeckaert F; Meyvisch P; Van Beirendonck E; Simmen K; Verloes R
    Gastroenterology; 2010 Mar; 138(3):913-21. PubMed ID: 19852962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection.
    Lawitz E; Rodriguez-Torres M; Denning JM; Albanis E; Cornpropst M; Berrey MM; Symonds WT
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1209-17. PubMed ID: 23263000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects.
    Sun C; Liu H; Ouyang Z; Ding J; Zhang Q; Ma H; Xu D; Zhang Q; Zhou R; Yang M; Hu W
    Expert Opin Investig Drugs; 2024 May; 33(5):533-542. PubMed ID: 38662639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects.
    Denning J; Cornpropst M; Flach SD; Berrey MM; Symonds WT
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1201-8. PubMed ID: 23262999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JTK-853, a novel non-nucleoside hepatitis C virus polymerase inhibitor, demonstrates a high genetic barrier to resistance in vitro.
    Ando I; Ogura N; Toyonaga Y; Hirahara K; Shibata T; Noguchi T
    Intervirology; 2013; 56(5):302-9. PubMed ID: 24008863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of the effect of food and omeprazole on the relative bioavailability of a single oral dose of 240 mg faldaprevir, a selective inhibitor of HCV NS3/4 protease, in an open-label, randomized, three-way cross-over trial in healthy participants.
    Wu J; Gießmann T; Lang B; Elgadi M; Huang F
    J Pharm Pharmacol; 2016 Apr; 68(4):459-66. PubMed ID: 27019158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
    Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
    Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, Safety, and Tolerability Following Single and Multiple Doses of Pibrentasvir in a First-in-Human Study.
    Lin CW; Dutta S; Asatryan A; Wang H; Clifton J; Campbell A; Liu W
    Clin Pharmacol Drug Dev; 2018 Jan; 7(1):44-52. PubMed ID: 28464496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Single and Multiple Ascending Dose Study of Toll-Like Receptor 7 Agonist (RO7020531) in Chinese Healthy Volunteers.
    Luk A; Jiang Q; Glavini K; Triyatni M; Zhao N; Racek T; Zhu Y; Grippo JF
    Clin Transl Sci; 2020 Sep; 13(5):985-993. PubMed ID: 32268000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects.
    McClure MW; Berliba E; Tsertsvadze T; Streinu-Cercel A; Vijgen L; Astruc B; Patat A; Westland C; Chanda S; Zhang Q; Kakuda TN; Vuong J; Khorlin N; Beigelman L; Blatt LM; Fry J
    PLoS One; 2018; 13(10):e0204974. PubMed ID: 30325939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design.
    Hotho DM; de Bruijne J; O'Farrell AM; Boyea T; Li J; Bracken M; Li X; Campbell D; Guler HP; Weegink CJ; Schinkel J; Molenkamp R; van de Wetering de Rooij J; van Vliet A; Janssen HL; de Knegt RJ; Reesink HW
    Antivir Ther; 2012; 17(2):365-75. PubMed ID: 22293533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
    Ogata K; Mendell-Harary J; Tachibana M; Masumoto H; Oguma T; Kojima M; Kunitada S
    J Clin Pharmacol; 2010 Jul; 50(7):743-53. PubMed ID: 20081065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.